Supremex Announces Results for the Third Quarter of 2025 GlobeNewswire November 06, 2025 MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Supremex Inc. (“Supremex” or the “Company”) (TSX: SXP), a leading North American manufacturer and marketer of envelopes and a growing provider of paper-based packaging solutions, today announced its results for the third quarter ended September […]
(NasdaqGM:WW), End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA1 of $43 million and Adjusted EBITDA Margin1 of 24.9% Narrowing 2025 Guidance to the higher
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 06, 2025 Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2 pediatric basket trial of Descartes-08
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire November 06, 2025 Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program GlobeNewswire November 06, 2025 One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06,
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates GlobeNewswire November 06, 2025 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief
Gogo Announces Third Quarter 2025 Results GlobeNewswire November 06, 2025 Total Revenue of $223.6 million, up 122% Year-over-Year; Service Revenue of $190.0 million, up 132% Year-over-Year Net Loss of $1.9 million, which includes a $15 million pre-tax acquisition-related earn-out accrual Adjusted EBITDA(1) of $56.2 million, up 61% Year-over-Year Over 200 Year to Date shipments of
LENSAR(R) Reports Third Quarter 2025 Results and Provides Business Update GlobeNewswire November 06, 2025 18 ALLY Robotic Cataract Laser Systems(R) (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 2024 ORLANDO, Fla.,
Matrix Service Company Announces Award for the Balance of Plant Supporting a Large, Dual Service Full Containment Storage Tank for Delaware River Partners GlobeNewswire November 06, 2025 TULSA, Okla., Nov. 06, 2025 (GLOBE NEWSWIRE) — Matrix Service Company (Nasdaq: MTRX), a leading contractor to the energy and industrial markets across North America, today announced that
Harvard Bioscience Announces Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by Operations Company Expects to Refinance or Repay the Debt in the Fourth Quarter Fourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline